Revotar Biopharmaceuticals AG appointed Dr. Gerhard Wolff, M.D. as Vice President Research & Development
Revotar Biopharmaceuticals AG announced the appointment of Dr. Gerhard Wolff, M.D. as Executive Vice President, Research & Development of the company.
Dr. Wolff is a Board certified physician with specialty in Internal Medicine. He received his medical degree in 1992 from the University of Leipzig, Germany and postgraduate training in molecular medicine at the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany, the Heart, Lung and Blood Institute at the National Institute of Health, Bethesda Maryland and at the Weill Medical College, Cornell University New York, USA. Currently, he holds associate lecturer positions at the University of Applied Science of Berlin and at the Charité of the Humboldt-University of Berlin, Germany. In parallel to his academic career, he participated and headed preclinical and clinical development projects with several pharmaceutical companies including Genzyme, Genentech, GenVec, Hoechst, or Schering AG. In 2002
Dr. Wolff joined Revotar as Director Development to conduct the clinical development program of bimosiamose, the first-in-class selectin antagonist and Revotar's leading product. Upon the success of the clinical program and the progress of the corresponding discovery projects, Revotar created the new position to coordinate and synergize the activities of discovery and development of selectin antagonists.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
